Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2

Active, not recruiting

Conditions: Testicular Cancer
Seminoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-05-06

Last Posted Date: 2024-06-25

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 135

Registration Number: NCT03937843

Locations: 🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Hopital de Sion, Sion, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 16 locations

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Endostar
Drug: Cisplatin
Radiation: Intensity Modulated Radiation Therapy (IMRT)
Drug: Docetaxel

First Posted Date: 2019-04-30

Last Posted Date: 2019-04-30

Lead Sponsor: Jiangsu Cancer Institute & Hospital

Target Recruit Count: 73

Registration Number: NCT03932266

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Interventions: Drug: ZW25 (Zanidatamab)
Drug: Cisplatin
Drug: Capecitabine
Drug: Gemcitabine
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2019-04-29

Last Posted Date: 2024-10-18

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT03929666

Locations: 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 18 locations

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date: 2019-04-24

Last Posted Date: 2019-04-24

Lead Sponsor: Xijing Hospital

Target Recruit Count: 300

Registration Number: NCT03925233

Locations: 🇨🇳
JingSu, Xi'an, Shaanxi, China

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Phase 3

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Cisplatin
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Placebo

First Posted Date: 2019-04-23

Last Posted Date: 2024-12-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 907

Registration Number: NCT03924856

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸
Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033), Seattle, Washington, United States
🇺🇸
Scripps MD Anderson ( Site 0010), La Jolla, California, United States

and more 172 locations

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3

Completed

Conditions: Recurrent or Metastatic Nasopharyngeal Cancer

Interventions: Drug: Placebo
Drug: Tislelizumab
Drug: Gemcitabin
Drug: Cisplatin

First Posted Date: 2019-04-23

Last Posted Date: 2024-07-16

Lead Sponsor: BeiGene

Target Recruit Count: 263

Registration Number: NCT03924986

Locations: 🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China

and more 37 locations

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1

Withdrawn

Conditions: Advanced and/or Metastatic Solid Tumors
Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Interventions: Drug: Retifanlimab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2019-04-19

Last Posted Date: 2020-04-24

Lead Sponsor: Incyte Corporation

Registration Number: NCT03920839

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Phase 1

Active, not recruiting

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions: Biological: Nivolumab
Drug: 5-FU
Drug: CDDP
Drug: DTX

First Posted Date: 2019-04-16

Last Posted Date: 2023-11-09

Lead Sponsor: National Cancer Center, Japan

Target Recruit Count: 36

Registration Number: NCT03914443

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Japan

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Squamous Cell Carcinoma
Bladder Urothelial Carcinoma
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Infiltrating Bladder Urothelial Carcinoma With Giant Cells
Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation
Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant
Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant